Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies

[1]  J. Mascola,et al.  Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Immunogenetic Considerations Underlying B-Cell Biology in the Development of a Pan-Subtype Influenza A Vaccine Targeting the Hemagglutinin Stem. , 2018, Cold Spring Harbor perspectives in biology.

[2]  A. García-Sastre,et al.  Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential Target Antigens and Critical Aspects for a Universal Influenza Vaccine. , 2018, Cold Spring Harbor perspectives in biology.

[3]  F. Scorza,et al.  New Kids on the Block: RNA-Based Influenza Virus Vaccines , 2018, Vaccines.

[4]  D. Weissman,et al.  mRNA vaccines — a new era in vaccinology , 2018, Nature Reviews Drug Discovery.

[5]  Seth J. Zost,et al.  Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains , 2017, Proceedings of the National Academy of Sciences.

[6]  M. Fotin‐Mleczek,et al.  Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines , 2017, npj Vaccines.

[7]  I. Wilson,et al.  A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine , 2017, PLoS pathogens.

[8]  R. Albrecht,et al.  A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies , 2017, npj Vaccines.

[9]  Kimberly J. Hassett,et al.  Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  D. Christensen,et al.  Robust antibody and CD8+ T-cell responses induced by P. falciparum CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection , 2017, npj Vaccines.

[11]  R. Hai,et al.  Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model , 2017, Journal of Virology.

[12]  D. Weissman,et al.  Zika virus protection by a single low dose nucleoside modified mRNA vaccination , 2017, Nature.

[13]  Nicole M. Bouvier,et al.  Defining the antibody cross-reactome against the influenza virus surface glycoproteins , 2017, Nature Immunology.

[14]  Caitlin E. Mullarkey,et al.  Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact , 2016, Proceedings of the National Academy of Sciences.

[15]  S. Bertholet,et al.  Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge , 2016, PloS one.

[16]  Daniel G. Anderson,et al.  Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose , 2016, Proceedings of the National Academy of Sciences.

[17]  Caitlin E. Mullarkey,et al.  Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection. , 2016, Cell host & microbe.

[18]  F. Krammer.  Novel universal influenza virus vaccine approaches. , 2016, Current opinion in virology.

[19]  R. Varadarajan,et al.  Stalking influenza by vaccination with pre-fusion headless HA mini-stem , 2016, Scientific Reports.

[20]  D. Weissman,et al.  Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[21]  P. Mason,et al.  Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin , 2015, Journal of Virology.

[22]  Adrian Apetri,et al.  A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen , 2015, Science.

[23]  J. Mascola,et al.  Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection , 2015, Nature Medicine.

[24]  T. Schlake,et al.  Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  Steven F. Baker,et al.  High-Affinity H7 Head and Stalk Domain-Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine After Priming With Live Attenuated Influenza Vaccine. , 2015, The Journal of infectious diseases.

[26]  P. Palese,et al.  Advances in the development of influenza virus vaccines , 2015, Nature Reviews Drug Discovery.

[27]  K. Subbarao,et al.  Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine. , 2014, Vaccine.

[28]  R. Karron,et al.  A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. , 2014, The Journal of infectious diseases.

[29]  P. Palese,et al.  Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo , 2014, Nature Medicine.

[30]  P. Palese,et al.  Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. , 2013, Journal of visualized experiments : JoVE.

[31]  Florian Krammer,et al.  Influenza virus hemagglutinin stalk-based antibodies and vaccines. , 2013, Current opinion in virology.

[32]  K. G. Rajeev,et al.  Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  J. Plotkin,et al.  Immune history shapes specificity of pandemic H1N1 influenza antibody responses , 2013, The Journal of experimental medicine.

[34]  R. Hai,et al.  Chimeric Hemagglutinin Influenza Virus Vaccine Constructs Elicit Broadly Protective Stalk-Specific Antibodies , 2013, Journal of Virology.

[35]  T. Schlake,et al.  Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection , 2012, Nature Biotechnology.

[36]  Jens C. Krause,et al.  A Carboxy-Terminal Trimerization Domain Stabilizes Conformational Epitopes on the Stalk Domain of Soluble Recombinant Hemagglutinin Substrates , 2012, PloS one.

[37]  Shigeo Matsuda,et al.  Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo** , 2012, Angewandte Chemie.

[38]  R. Albrecht,et al.  Influenza Viruses Expressing Chimeric Hemagglutinins: Globular Head and Stalk Domains Derived from Different Subtypes , 2012, Journal of Virology.

[39]  Adolfo García-Sastre,et al.  Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses , 2012, Proceedings of the National Academy of Sciences.

[40]  F. Ennis,et al.  Complement-Dependent Lysis of Influenza A Virus-Infected Cells by Broadly Cross-Reactive Human Monoclonal Antibodies , 2011, Journal of Virology.

[41]  D. Weissman,et al.  Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA , 2011, Nucleic acids research.

[42]  W. C. Hwang,et al.  Wide Prevalence of Heterosubtypic Broadly Neutralizing Human Anti–Influenza A Antibodies , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  G. Nabel,et al.  Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination , 2010, Science.

[44]  K. Subbarao,et al.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. , 2010, The Journal of clinical investigation.

[45]  James E. Crowe,et al.  Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus , 2010, Science.

[46]  Hiroki Kato,et al.  Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[47]  Stephen C. Jones,et al.  CD4+ T‐cell memory: generation and multi‐faceted roles for CD4+ T cells in protective immunity to influenza , 2006, Immunological reviews.

[48]  D. Weissman,et al.  Nucleoside Modified mRNA Vaccines for Infectious Diseases. , 2017, Methods in molecular biology.

[49]  A. García-Sastre,et al.  Is It Possible to Develop a “Universal” Influenza Virus Vaccine? Toward a Universal Influenza Virus Vaccine: Potential Target Antigens and Critical Aspects for Vaccine Development , 2017 .

[50]  D. Weissman,et al.  HPLC purification of in vitro transcribed long RNA. , 2013, Methods in molecular biology.

[51]  D. Weissman,et al.  In vitro transcription of long RNA containing modified nucleosides. , 2013, Methods in molecular biology.